---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087873"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:30:40.722427+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Appoints Ted Love, M.D. to Board; amends director compensation policy

## Summary
- Ted Love, M.D. appointed as Class III director and Chair of Compensation Committee effective August 3, 2023.
- Board size reduced to seven directors; Love determined independent under Nasdaq listing standards.
- Initial option grant for new non-employee directors increased to 75,000 ordinary shares (25,000 ADSs).
- Annual option grant set at 37,500 ordinary shares (12,500 ADSs); post-termination exercise period extended for trust transfers.
- Love receives initial grant of 75,000 shares vesting over 36 months plus cash retainers of $45,000 and $10,000.

## SEC filing metadata
- accession: 0001104659-23-087873
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923087873/0001104659-23-087873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923087873/tm2322858d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087873
- JSON: https://secwatch.observer/filing/0001104659-23-087873.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087873.txt

## Key facts
- Executive change
  Ted Love, M.D. was appointed as Class III director and Chair of the Compensation Committee at Structure Therapeutics Inc..
  - Action: appointed
  - Role: Class III director and Chair of the Compensation Committee
  source text: appointed Ted Love, M.D. to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923087873/0001104659-23-087873-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.